Home » Newsletters » BioWorld Science

BioWorld Science

June 18, 2012

View Archived Issues

Multiple insulin degludec trials presented at recent conferences

Canadian study links gene's copy number to ankylosing spondylitis

New model allows assessment of two islet preparations in one primate

Novel apoptosis inducers created at IMPACT Therapeutics

First-in-human data presented on oncolytic BAY-1000394

Simcere presents new calcium channel blockers/acetylcholinesterase inhibitors

Eli Lilly designs novel metabotropic glutamate receptor antagonists

Sunovion reports Canadian approval of once-daily schizophrenia therapy

Anergis achieves preclinical milestones

Civitas Therapeutics advances inhaled levodopa formulation to phase IIa

Sublingual drug for sleep disorders approved in Europe

AstraZeneca and Dainippon Sumitomo jointly patent new oncolytics

New tau-detecting diagnostics developed by GE Healthcare and Medi-Physics

Portola updates on trial of universal factor Xa inhibitor antidote

Phase II study tests iron chelator in adults with transfusional iron overload

EPFL reports novel antibacterials

Dyax discontinues trial of drug for ACE inhibitor-induced angioedema

Wilex oral uPA inhibitor is efficacious in proof-of-concept study

Lysogene advances gene therapy study in Sanfilippo type A syndrome

Janssen files applications to extend Zytiga indication

Debiopharm and Ascepion enter license agreement for multikinase inhibitor

Bavarian Nordic receives government contract for MVA-BN-based vaccines

Valeant Pharmaceuticals to acquire oral health product company

Tosedostat studied for elderly patients with AML or high-risk MDS

First clinical data disclosed on Bristol-Myers Squibb drug for cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...